The geneMAP™ BCR-ABL1 P210 IS-MMR Detection Kit is intended for the quantitative detection of BCR-ABL1 p210 b2a2 and b3a2 fusion transcripts in bone marrow or peripheral blood samples of patients who have been diagnosed with Acute Lymphoblastic Leukemia (ALL) or Chronic Myeloid Leukemia(CML). The test is intended to evaluate the level of molecular response. This test can be used to monitor Minimal Residual Disease (MRD) in patients undergoing therapy. The test does not differentiate between e13a2/b2a2 or e14a2/b3a2 fusion transcripts and does not monitor other rare fusion transcripts resulting from t(9;22).
Quantitative determination of BCR-ABL1 fusion gene b3a2(e14a2) and b2a2(e13a2) transcripts.
- Ultra Sensitive: LOG (10-5) (NCN-IS %: 0.001) detection of BCR-ABL1 transcript.
- Fast and Easy to use with One Step RT-qPCR technology.
- International Scale results(IS-MMR).
- Primer probe mix, target gene and reference gene (ABL) are all in one tube (MULTIPLEX).
- ABL1 as a reference gene.
- Six standards for quantitation.
- Automatic analysis with geneMAP viewer (for CFX96TM / BIO-RAD).
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
